Acute promyelocytic leukemia · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ATRA monotherapy Variant #01 | — | R 44 112 | — | — | — | — | — | — |
ATRA, Mercaptopurine, Methotrexate Variant #01 | — | R 15 027 | 90d | — | — | — | — | — |
Mercaptopurine and Methotrexate Variant #05 | — | R 2 336 | 14d | — | — | — | — | — |
Arsenic trioxide monotherapy N/A - intrathecal component | — | R 0 | — | — | — | — | — | — |
Observation Partial | — | — | — | — | ~14.8 mo | — | — | — |
5 of 5 regimens shown